BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 24.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 463,955 shares of the biopharmaceutical company’s stock after selling 147,341 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Gilead Sciences were worth $35,822,000 at the end of the most recent quarter.
Several other hedge funds have also bought and sold shares of GILD. Bank of New York Mellon Corp boosted its stake in Gilead Sciences by 199,789.8% during the third quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock worth $2,420,587,000 after buying an additional 31,335,030 shares during the period. Northern Trust Corp boosted its stake in Gilead Sciences by 2.0% during the second quarter. Northern Trust Corp now owns 16,823,192 shares of the biopharmaceutical company’s stock worth $1,191,754,000 after buying an additional 325,246 shares during the period. Alliancebernstein L.P. boosted its stake in Gilead Sciences by 2.3% during the third quarter. Alliancebernstein L.P. now owns 10,591,252 shares of the biopharmaceutical company’s stock worth $817,751,000 after buying an additional 241,790 shares during the period. Boston Partners boosted its stake in Gilead Sciences by 3.1% during the second quarter. Boston Partners now owns 8,290,507 shares of the biopharmaceutical company’s stock worth $587,300,000 after buying an additional 245,805 shares during the period. Finally, OppenheimerFunds Inc. boosted its stake in Gilead Sciences by 0.3% during the second quarter. OppenheimerFunds Inc. now owns 7,038,387 shares of the biopharmaceutical company’s stock worth $498,599,000 after buying an additional 22,916 shares during the period. 78.19% of the stock is owned by hedge funds and other institutional investors.
In other news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $69.55, for a total transaction of $3,477,500.00. Following the completion of the sale, the director now directly owns 3,067,762 shares in the company, valued at $213,362,847.10. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have sold 150,000 shares of company stock valued at $11,087,500. Corporate insiders own 1.16% of the company’s stock.
NASDAQ:GILD opened at $71.94 on Monday. Gilead Sciences, Inc. has a twelve month low of $64.27 and a twelve month high of $89.54. The firm has a market cap of $93.06 billion, a PE ratio of 8.40, a price-to-earnings-growth ratio of -2.79 and a beta of 1.01. The company has a quick ratio of 3.37, a current ratio of 3.45 and a debt-to-equity ratio of 1.09.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.21. Gilead Sciences had a return on equity of 39.32% and a net margin of 7.12%. The business had revenue of $5.60 billion during the quarter, compared to the consensus estimate of $5.44 billion. During the same period last year, the company earned $2.27 earnings per share. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 6.44 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 28th. Stockholders of record on Friday, December 14th will be given a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, December 13th. This represents a $2.28 annualized dividend and a dividend yield of 3.17%. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Story: What strategies should day traders use to execute a trade?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.